Breaking News
June 20, 2018 - Why are vaccines less effective in the developing world?
June 20, 2018 - Study opens new window into cellular events that occur in the brain during absence seizures
June 20, 2018 - Humana and Walgreens to provide easier access to primary care and other services for seniors
June 20, 2018 - ANU research could help find life in Mars and other planets
June 20, 2018 - Multidisciplinary Human-Focused Research
June 20, 2018 - New study finds increase in use of alternative medicines among children
June 20, 2018 - Elevated NT-proBNP Found to Up Cardiovascular Risk in T2DM
June 20, 2018 - Genetics Home Reference: White-Sutton syndrome
June 20, 2018 - Canadian team reports success in transplanting hepatitis C organs
June 20, 2018 - Separating migrant children from parents at US border tantamount to child abuse
June 20, 2018 - Study finds more information about how gene linked to ASD affects the brain
June 20, 2018 - Floppy eyelids linked to sleep apnea
June 20, 2018 - Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson
June 20, 2018 - KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug response assay
June 20, 2018 - Study finds growing support to allow pharmacists to write prescriptions
June 20, 2018 - LabConnect collaborates with Symphony to support clinical research industry
June 20, 2018 - Italian innovative SME receives 2.5 million Euro from RedSeed Ventures
June 20, 2018 - AHA: Kids Can Drown Quickly and Silently, So Prevention Is Key
June 20, 2018 - Continuous glucose monitors proven cost-effective, add to quality of life for diabetics
June 20, 2018 - Researchers use droplet-sized ‘miniecosystems’ to test therapeutic potential of molecules
June 20, 2018 - New approach could provide objective and easy-to-obtain measure of dietary adherence
June 20, 2018 - Dual-therapy approach can help boost motor recovery in stroke victims
June 20, 2018 - ‘Miracle treatment’ long-term success for babies with diabetes
June 20, 2018 - Rheumatoid Arthritis patients with depression have increased risk of disease flare
June 20, 2018 - NTU launches new research centers to prevent and treat diseases affecting Singaporeans
June 20, 2018 - Merck enters into agreement with HistoCyte Laboratories to distribute cell line reference products
June 20, 2018 - Researchers examine risk factors for opioid dependence in patients undergoing surgery for DS
June 20, 2018 - Study finds substantial variation in cardiovascular risk across India
June 20, 2018 - Kidney donation among carefully-selected older adults poses minimal risks
June 20, 2018 - Effects of atrial fibrillation can be reduced or reversed by losing weight
June 20, 2018 - Allergan’s Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
June 20, 2018 - The novel insights of proteoglycans in mineralized tissues
June 20, 2018 - Scientists shed light on key aspect of healthy cell division
June 20, 2018 - Circulating bone turnover markers not linked to hip fracture risk, shows study
June 20, 2018 - Scientists obtain key information about proteins from single human cells
June 20, 2018 - Scientists identify novel genes linked with infantile forms of schizophrenia
June 20, 2018 - Low-dose aspirin could help pregnant women with high blood pressure avoid a dangerous condition
June 20, 2018 - Unusual gene provides novel insight into how the brain wires itself
June 20, 2018 - Study finds IV acetaminophen to be no more effective than oral counterpart for colectomy patients
June 20, 2018 - MAARA to celebrate its 50th anniversary with lecture titled ‘The Future of Asthma’
June 20, 2018 - Administration eases way for small businesses to buy insurance in bulk
June 20, 2018 - High-Quality Diet May Decrease Mortality Risk in Cancer Survivors
June 20, 2018 - JAMA editorial on ECG screening and cardiac risks
June 20, 2018 - Study hints at benefits of lifestyle interventions in reducing dementia risk
June 20, 2018 - Low blood levels of vitamin D linked to increased risk of interstitial lung disease
June 20, 2018 - Simple cognitive task after brain injury improves memory function, study finds
June 20, 2018 - Clinical trial targets metastatic colorectal cancer with new combination therapy
June 20, 2018 - Researchers discover pesticide-free way to limit mosquitoes and reduce spread of West Nile virus
June 20, 2018 - Persistent psychological stress contributes to development and progression of vision loss
June 20, 2018 - Study introduces novel strategy to obtain reasonable drug cost estimates for cost-effectiveness analyses
June 20, 2018 - Does Salt Water Help Your Cut? And Other Health Myths of Summer
June 20, 2018 - Scientists help identify genetic markers for prostate cancer in global DNA download
June 19, 2018 - Common ingredient in toothpaste and hand wash could contribute to antibiotic resistance
June 19, 2018 - WHO launches multiyear campaign to eliminate use of trans fat
June 19, 2018 - Scientists could build better drugs by learning from bacteria-derived molecules
June 19, 2018 - Comparative silence between firing spikes of neurons reveals what they are really up to
June 19, 2018 - JAK inhibitors associated with aggressive lymphoma
June 19, 2018 - SetPoint announces positive long-term results of bioelectronic medicine to treat rheumatoid arthritis
June 19, 2018 - Hypnosis may help reduce fear, anxiety in children undergoing treatment for cancer
June 19, 2018 - Scientists point to potentially promising treatment target for deadly brain cancers
June 19, 2018 - After opioid overdose, only 30 percent get medicine to treat addiction
June 19, 2018 - Patients with mild Alzheimer’s disease over age 65 continue to derive benefit from DBS-f treatment
June 19, 2018 - Microbiotica partners with University of Adelaide to develop defined bacterial product for ulcerative colitis
June 19, 2018 - Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
June 19, 2018 - Autism is not linked to eating fish in pregnacy
June 19, 2018 - Scientists create universal assembly method to enhance cancer therapy and diagnostics
June 19, 2018 - Follow-up study confirms success of physiological test for autism
June 19, 2018 - FDA provides guidance on Novus Therapeutics’ development path for OP-02 to treat otitis media
June 19, 2018 - Scientists discover new mechanism controlling multiple sclerosis risk
June 19, 2018 - Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections
June 19, 2018 - Study finds combined risk of death and developing cancer to be lowest in light drinkers
June 19, 2018 - Novel app teaches users how to stop life-threatening bleeding and save lives
June 19, 2018 - Single blood sample can provide adequate confirmation of diabetes
June 19, 2018 - New stimulation method increases hope for improving disorders of consciousness
June 19, 2018 - FDA Issues Complete Response Letter for Duobrii (halobetasol propionate and tazarotene) Lotion
June 19, 2018 - Defining the biology of autism
June 19, 2018 - Researchers use optogenetics to shape tissues
June 19, 2018 - Scientists discover genetic causes underlying group of related infant cancers
June 19, 2018 - Innovative digital home testing kit benefits patients with kidney conditions
June 19, 2018 - New guidance on selection and evaluation of wearable devices for use in regulatory clinical trials
Eczema drug alleviates asthma symptoms and improves lung function

Eczema drug alleviates asthma symptoms and improves lung function

image_pdfDownload PDFimage_print

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients’ ability to breathe better than standard therapies. Dupilumab, an injectable anti-inflammatory drug, was approved in 2017 by the Food and Drug Administration as a treatment for eczema, a chronic skin disease.

Researchers at Washington University School of Medicine in St. Louis and other institutions conducted the studies and were scheduled to present the results May 20 and 21 at the 2018 American Thoracic Society Conference in San Diego. The studies also will be published online May 21 in The New England Journal of Medicine.

The more than 2,000 patients enrolled in the studies suffered from moderate to severe asthma. All used standard asthma inhalers, and some also took oral steroids to control their severe asthma symptoms.

In one study, the rate of asthma exacerbations was almost cut in half for those taking dupilumab compared with those taking a placebo. On average, patients taking a placebo had close to one exacerbation per day during the year of the study. Exacerbations are periods of sudden worsening of asthma symptoms such as wheezing, coughing, shortness of breath and tightness in the chest.

Although the drug significantly reduced asthma symptoms for all patients, dupilumab worked particularly well in patients with high numbers of a specific type of white blood cell, called eosinophils, circulating in the bloodstream. For those patients, asthma exacerbations were cut by two-thirds.

“This drug not only reduced severe symptoms of asthma, it improved the ability to breathe,” said Mario Castro, MD, the Alan A. and Edith L. Wolff Distinguished Professor of Pulmonology and Critical Care Medicine. “That’s important because these patients have a chronic disabling disease that worsens over time with loss of lung function. So far, we do not have a drug for asthma that changes the course of the disease. Current drugs for severe asthma help reduce trips to the emergency room, for example, but they don’t improve lung function.”

The first study included about 1,900 patients of at least 12 years of age and with moderate to severe asthma requiring they use at least three different inhalers to control their symptoms. One inhaler contained a corticosteroid that reduces inflammation, another contained a long-acting bronchodilator that relaxes airway muscles, and the third was a “rescue” inhaler filled with albuterol, a short-acting bronchodilator that quickly opens up the airway in the event of a more severe asthma attack.

Patients taking these inhaled medications then were randomly assigned to receive either dupilumab or a placebo for one year. Patients receiving dupilumab -; an injectable antibody -; also were randomly assigned to a higher or lower dose of the drug. Neither patients nor their doctors knew whether they were receiving the drug or the placebo.

In addition to reduced symptoms, the patients receiving dupilumab showed improved lung function in a test of “forced expiratory volume.” This test measures the amount of air a person can force from the lungs during a deep exhale. Patients receiving dupilumab, regardless of dose, improved their lung function by approximately 130-200 milliliters greater than those receiving the placebo. In general, there were no significant differences between the patients receiving high and low doses of dupilumab.

Rates of emergency room (ER) visits and hospitalizations also were improved for patients receiving the drug. In the placebo group (with 638 patients), on average, 6.5 percent of the patients required an emergency room visit or hospitalization due to asthma during the study. In the dupilumab group (with 1,264 patients), on average, 3.5 percent of patients needed emergency care or hospitalization due to asthma.

Based on the second study, Castro said another benefit of the drug could be the ability to wean severe asthma patients off of chronic oral steroids, which can cause debilitating long-term side effects, including stunted growth, diabetes, cataracts and osteoporosis. The second study included about 200 patients using the same inhaled asthma medications as patients in the larger trial, plus additional oral steroids -; usually prednisone -; to control their more severe symptoms. Half of the patients receiving dupilumab in this study were able to completely eliminate prednisone use. And 80 percent of dupilumab-treated patients were able to at least cut their doses in half. Patients on placebo also reduced prednisone use but to a lesser degree, likely because the protocols of participating in a clinical trial help asthma control generally.

Castro said doctors would like to help patients rely less on steroids for asthma control because those with severe asthma can be forced to take these drugs for decades to enable them to breathe.

“I have patients who have had to stop working and go on disability because their asthma symptoms are so severe they can no longer function in the workplace,” Castro said. “I’m excited about the potential of dupilumab because I have so many patients who have maxed out on available therapies and they still can’t breathe. It can become a very disabling disease.”

Patients receiving dupilumab did experience known side effects of the drug, including pain and swelling at the injection site and a short-term bump in the number of eosinophil cells in the blood. Five patients who received dupilumab and three patients who received placebo died during the study period. According to the investigators and descriptions of these patients’ medical histories, all suffered from multiple severe medical conditions, and none of the deaths was deemed related to the study protocol.

Source:

Eczema drug effective against severe asthma

Tagged with:

About author

Related Articles